Antibody passing through the blood-cerebrospinal fluid barrier

JP2025523630A5Pending Publication Date: 2026-07-13VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025500085
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-08-31
Filing Date
2023-07-04
Publication Date
2026-07-13

AI Technical Summary

Technical Problem

The development of drugs for the central nervous system (CNS) is hindered by the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB), which limit the bioavailability of pharmaceutical compounds, leading to high-dose administration risks and strain on antibody production capacity, particularly in conditions like Alzheimer's disease and multiple sclerosis.

Method used

Development of single domain antibodies, specifically VHHs, that bind to the human folate receptor alpha (FRα) in choroid plexus epithelial cells, facilitating the delivery of compounds across the BCSFB through receptor-mediated endocytosis and transcytosis.

Benefits of technology

The antibodies enable efficient delivery of therapeutic and diagnostic agents across the BCSFB with a single systemic administration, reducing the need for high-dose administration and minimizing peripheral side effects, while enhancing bioavailability in the brain.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000078_0000
    Figure 00000078_0000
  • Figure 00000078_0001
    Figure 00000078_0001
  • Figure 00000078_0002
    Figure 00000078_0002
Patent Text Reader

Abstract

The present invention relates to a binder that specifically binds to a folate transport complex. More specifically, an antibody or antibody fragment is disclosed that includes an immunoglobulin single variable domain (ISVD) antibody that binds to human folate receptor alpha (hFOLRα) present in choroid plexus epithelial cells. The present invention further relates to the antibodies and methods described herein for use in increasing the delivery of pharmaceutical compounds to the central nervous system through the process of receptor-mediated endocytosis and / or transcytosis.
Need to check novelty before this filing date? Find Prior Art